Small-molecule-induced ERBB4 activation to treat heart failure

Small-molecule-induced ERBB4 activation to treat heart failure

Abstract Heart failure is a common and deadly disease requiring new treatments. The neuregulin-1/ERBB4 pathway offers cardioprotective benefits, but using recombinant neuregulin-1 as therapy has limitations due to the need for intravenous delivery and lack of receptor specificity. We hypothesize tha...

Full description

Bibliographic Details
Main Authors: Julie M. T. Cools, Bo K. Goovaerts, Eline Feyen, Siel Van den Bogaert, Yile Fu, Céline Civati, Jens Van fraeyenhove, Michiel R. L. Tubeeckx, Jasper Ott, Long Nguyen, Eike M. Wülfers, Benji Van Berlo, Antoine A. F. De Vries, Nele Vandersickel, Daniël A. Pijnappels, Dominique Audenaert, H. Llewelyn Roderick, Hans De Winter, Gilles W. De Keulenaer, Vincent F. M. Segers
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-54908-5

Internet

https://doi.org/10.1038/s41467-024-54908-5

Similar Items